Belite Bio, Inc (BLTE)

NASDAQ: BLTE · Delayed Price · USD
14.27
0.19 (1.35%)
At close: May 25, 2022 3:50 PM
14.80
0.53 (3.71%)
After-hours:May 25, 2022 6:34 PM EDT
Market Cap343.84M
Revenue (ttm)n/a
Net Income (ttm)-9.67M
Shares Out24.10M
EPS (ttm)-0.40
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume11,507
Open14.20
Previous Close14.08
Day's Range14.20 - 14.62
52-Week Range8.80 - 17.50
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About BLTE

Belite Bio is a clinical stage biopharmaceutical drug development company focused on novel therapeutics targeting currently untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration (commonly known as dry AMD) and autosomal recessive Stargardt disease, or STGD1, both of which progressively lead to permanent blindness, and, at the preclinical development stage, metabolic diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. Our lead product can...

IndustryBiotechnology
IPO DateApr 29, 2022
CEOYu-Hsin Lin
Employees12
Stock ExchangeNASDAQ
Ticker SymbolBLTE
Full Company Profile

Financial Performance

Financial Statements

News

Belite Bio Announces Partial Exercise of Over-Allotment Option in Initial Public Offering

SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug development company targeting currently untreatable eye di...

1 week ago - GlobeNewsWire

Belite Bio Presented Interim Results of LBS-008 Phase 1b/2 Study in Adolescent STGD1 at ARVO Annual Meeting 2022

SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (the “Company”) (Nasdaq: BLTE),  a San Diego based clinical stage biopharmaceutical drug development company targeting currently untreatable e...

2 weeks ago - GlobeNewsWire